Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?
Publication
, Journal Article
Drew, RH
Published in: Ann Pharmacother
April 2007
The changing epidemiology of invasive candidiasis, along with concerns for the emergence of drug resistance, necessitates the identification of patients at increased risk of non-albicans Candida (NAC) to optimize selection of antifungal therapy. The major findings of a study regarding the demographic characteristics, costs, and outcomes of nonneutropenic patients with candidemia due to NAC are discussed. Given available treatment options, such risk assessment is most relevant to initial empiric therapy in stable patients without neutropenia who might be candidates for initial therapy with an azole (eg, fluconazole). The study's investigators reinforce the need for timely antifungal therapy for patients with candidemia.
Duke Scholars
Published In
Ann Pharmacother
DOI
EISSN
1542-6270
Publication Date
April 2007
Volume
41
Issue
4
Start / End Page
690 / 692
Location
United States
Related Subject Headings
- Risk Assessment
- Pharmacology & Pharmacy
- Humans
- Fluconazole
- Candidiasis
- Antifungal Agents
- 3214 Pharmacology and pharmaceutical sciences
- 3202 Clinical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Drew, R. H. (2007). Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? Ann Pharmacother, 41(4), 690–692. https://doi.org/10.1345/aph.1K051
Drew, Richard H. “Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?” Ann Pharmacother 41, no. 4 (April 2007): 690–92. https://doi.org/10.1345/aph.1K051.
Drew RH. Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? Ann Pharmacother. 2007 Apr;41(4):690–2.
Drew, Richard H. “Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?” Ann Pharmacother, vol. 41, no. 4, Apr. 2007, pp. 690–92. Pubmed, doi:10.1345/aph.1K051.
Drew RH. Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? Ann Pharmacother. 2007 Apr;41(4):690–692.
Published In
Ann Pharmacother
DOI
EISSN
1542-6270
Publication Date
April 2007
Volume
41
Issue
4
Start / End Page
690 / 692
Location
United States
Related Subject Headings
- Risk Assessment
- Pharmacology & Pharmacy
- Humans
- Fluconazole
- Candidiasis
- Antifungal Agents
- 3214 Pharmacology and pharmaceutical sciences
- 3202 Clinical sciences
- 1115 Pharmacology and Pharmaceutical Sciences